Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Pasritamig · KLCB-245

Bispecific antibody · Immune activation, directed at kallikrein-2 (hK2) (KLK2) and CD3 receptor complex · developed by Janssen Research & Development, LLC

Phase 1 Most advanced trial
JNJ Developer
1 Registered trials

What is Pasritamig?

Pasritamig is a humanized IgG1 bispecific antibody that binds kallikrein-2 (KLK2) on tumor cells and the CD3 receptor complex on T-cells. By cross-linking the two, it redirects T-cells to KLK2-expressing cells, causing their lysis. It is being studied in prostate cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
KLCB-245
Drug type
Bispecific antibody
Targets
kallikrein-2 (hK2) (KLK2), CD3 receptor complex
Mechanism
Immune activation, directed at kallikrein-2 (hK2) (KLK2) and CD3 receptor complex
Therapy area
Oncology
Developer
Janssen Research & Development, LLC (JNJ)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
NDM64RSJ42

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07860255 Phase 1 Prostate Cancer Not yet recruiting JNJ

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Prostate Cancer

More from Janssen Research & Development, LLC

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the JNJ page.

Follow JNJ, the company behind Pasritamig

See JNJ's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

JNJ catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.